Literature DB >> 22672485

Nonalcoholic fatty liver disease: the hepatic metabolic syndrome.

Jeni Page1.   

Abstract

PURPOSE: To examine a case of nonalcoholic fatty liver disease (NAFLD) and review the incidence, pathophysiology, appropriate diagnostic procedures and imaging, clinical considerations, and treatment options. DATA SOURCES: Findings from the history, physical examination, and diagnostic testing of a 39-year-old man with elevated liver enzymes presenting to the hepatology clinic; a search of evidence-based literature in the PubMed and CINAHL database with the terms "fatty liver,""nonalcoholic fatty liver disease," and "nonalcoholic steatohepatitis."
CONCLUSIONS: NAFLD is the deposition of fat in the liver that can progress to nonalcoholic steatohepatitis, resulting in fibrosis and cirrhosis. The exact pathophysiology is unknown, but risk factors can include those criteria associated with metabolic syndrome. NAFLD is a diagnosis of exclusion and can lead to serious health consequences if it is not identified and interventions are not implemented promptly. Treatment options remain limited but currently focus on weight loss, exercise, and diet. IMPLICATION FOR PRACTICE: The clinician must include the spectrum of NAFLD in the differential diagnosis for any patient with elevated liver enzymes. The key actions for diagnosing NAFLD are identifying risk factors and ordering appropriate testing for confirmation. These considerations will lead to early diagnosis and implementation of treatment interventions. ©2012 The Author(s) Journal compilation ©2012 American Academy of Nurse Practitioners.

Entities:  

Mesh:

Year:  2012        PMID: 22672485     DOI: 10.1111/j.1745-7599.2012.00716.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  3 in total

1.  Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats.

Authors:  Kosuke Tanaka; Yuko Masaki; Masatake Tanaka; Masayuki Miyazaki; Munechika Enjoji; Makoto Nakamuta; Masaki Kato; Masatoshi Nomura; Toyoshi Inoguchi; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

2.  Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study.

Authors:  Sofía Montemayor; Catalina M Mascaró; Lucía Ugarriza; Miguel Casares; Isabel Llompart; Itziar Abete; María Ángeles Zulet; J Alfredo Martínez; Josep A Tur; Cristina Bouzas
Journal:  Nutrients       Date:  2022-08-03       Impact factor: 6.706

3.  Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial.

Authors:  Elena S George; Anjana Reddy; Amanda J Nicoll; Marno C Ryan; Catherine Itsiopoulos; Gavin Abbott; Nathan A Johnson; Siddharth Sood; Stuart K Roberts; Audrey C Tierney
Journal:  Liver Int       Date:  2022-04-26       Impact factor: 8.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.